Leqembi Dosage: Form, Strengths, How It’s Given, and More

Leqembi dosage is not a “take one tablet with breakfast and call it a day” situation. Leqembi, also known by its generic name lecanemab-irmb, is a prescription Alzheimer’s disease treatment given on a carefully planned schedule, with brain imaging, weight-based dosing, and a healthcare team watching the calendar like it owes them money.

Leqembi is approved for the treatment of Alzheimer’s disease, with treatment started in people who have mild cognitive impairment or mild dementia stage of disease. Before treatment begins, doctors confirm that amyloid beta pathology is present. In plain English, that means the care team looks for evidence of the amyloid plaques that Leqembi is designed to target.

This guide explains Leqembi’s form, strengths, dosing schedule, how it is given, what happens after 18 months, what to know about missed doses, and what patients and caregivers can realistically expect from the treatment routine.

What Is Leqembi?

Leqembi is a monoclonal antibody. That sounds like something cooked up in a superhero lab, but it simply means it is a lab-made antibody designed to attach to a specific target in the body. In this case, Leqembi targets aggregated forms of amyloid beta, a protein associated with plaques in the brains of people with Alzheimer’s disease.

Leqembi is not a cure for Alzheimer’s disease. It does not reverse memory loss, rebuild lost brain cells, or magically help someone remember where they left their glasses in 2014. Its goal is different: to help reduce amyloid beta plaques and slow disease progression in certain people with early Alzheimer’s disease.

Leqembi Forms and Strengths

Leqembi is available in two main administration formats: an intravenous infusion form and a subcutaneous autoinjector form called Leqembi IQLIK. The right form depends on where a person is in treatment.

Intravenous Infusion Form

The original Leqembi form is a liquid solution supplied in single-dose vials. It is given by intravenous infusion, meaning the medication goes directly into a vein through an IV line. The solution must be diluted before it is administered.

The available IV vial strengths are:

• 200 mg/2 mL single-dose vial, equal to 100 mg/mL
• 500 mg/5 mL single-dose vial, equal to 100 mg/mL

These vials are used by healthcare professionals to prepare the correct dose based on the patient’s actual body weight.

Subcutaneous Injection Form: Leqembi IQLIK

Leqembi IQLIK is the subcutaneous form of lecanemab-irmb. “Subcutaneous” means the medication is injected under the skin. This version is supplied as a single-dose prefilled autoinjector.

The approved maintenance autoinjector strength is:

• 360 mg/1.8 mL, equal to 200 mg/mL

Leqembi IQLIK is used for maintenance dosing after the initial treatment period. It is not simply swapped in casually at the start like choosing oat milk instead of regular milk. The route and schedule should follow the prescribing plan set by the treating specialist.

Recommended Starting Dosage of Leqembi

The recommended starting dosage of Leqembi is:

10 mg per kg of body weight once every 2 weeks by IV infusion.

This starting dose is given over approximately one hour. Because the dose is weight based, two patients may receive different amounts of medication even though they are on the same dosing schedule.

Leqembi Dosage Example

Here is a simple example. If a person weighs 70 kg, the dose is calculated like this:

70 kg × 10 mg/kg = 700 mg

That person’s dose would be 700 mg every 2 weeks during the starting treatment period. The healthcare team calculates the exact amount, prepares the infusion, and determines how many vials are needed. Patients should not attempt to calculate, adjust, or “round up” their own dose. This is medicine, not a pizza order.

How Leqembi Is Given

How the IV Infusion Works

For IV treatment, Leqembi is diluted in 250 mL of 0.9% sodium chloride injection. A healthcare professional administers the infusion through an IV line over about one hour. The infusion typically takes place in a hospital, infusion center, neurology clinic, or another medical setting equipped to monitor patients.

During and after the infusion, the care team watches for possible infusion-related reactions. These may include fever, chills, body aches, nausea, vomiting, blood pressure changes, oxygen level changes, or flu-like symptoms. If a reaction occurs, the healthcare professional may slow the infusion, stop it, treat symptoms, or consider premedication before future infusions.

How the Subcutaneous Injection Works

Leqembi IQLIK is given under the skin once weekly for eligible maintenance treatment. Injection sites include the abdomen, upper thigh, or back of the upper arm. The medication should not be injected into areas that are bruised, tender, hard, red, scarred, tattooed, or otherwise irritated.

Before use, the autoinjector is typically allowed to sit at room temperature for about 20 minutes. It should not be shaken or warmed with an external heat source. Patients and caregivers must be trained on proper injection technique, and the healthcare team should periodically reassess whether home administration remains safe and appropriate.

What Happens After 18 Months?

After approximately 18 months of Leqembi IV treatment every 2 weeks, the healthcare provider may consider maintenance dosing. At that point, there are several possible paths:

• Continue IV Leqembi at 10 mg/kg once every 2 weeks
• Transition to IV maintenance dosing at 10 mg/kg once every 4 weeks
• Transition to Leqembi IQLIK at 360 mg once weekly by subcutaneous injection

If a patient transitions from the starting IV schedule to a maintenance schedule, the first maintenance dose is generally given two weeks after the last starting dose. During maintenance, patients may also switch between the IV and subcutaneous maintenance regimens. When switching maintenance routes, the transition is typically started one week after the last maintenance dose, then the new schedule is followed.

Why Leqembi Dosage Is Weight Based

The starting and IV maintenance dose of Leqembi is based on body weight because the amount of medicine needed to achieve the intended exposure can vary from person to person. Weight-based dosing is common for monoclonal antibodies and other biologic medications.

This is also why changes in body weight may matter. If a patient loses or gains a significant amount of weight, the healthcare team may recalculate the IV dose. The goal is not to chase every one-pound fluctuation after a salty dinner, but major weight changes should be discussed with the prescribing clinician.

Monitoring Before and During Leqembi Treatment

Leqembi requires more monitoring than many common medications. Before starting treatment, doctors confirm amyloid beta pathology and obtain a recent baseline brain MRI. MRI monitoring is important because Leqembi can cause amyloid-related imaging abnormalities, often shortened to ARIA.

ARIA can include swelling or fluid buildup in the brain, known as ARIA-E, or small areas of bleeding or iron deposits, known as ARIA-H. ARIA is often found on MRI before symptoms appear, which is why scheduled imaging matters.

Current monitoring recommendations include MRI scans before the 3rd, 5th, 7th, and 14th infusions, generally within about one week before the scheduled infusion. Additional MRIs may be needed if symptoms suggest ARIA.

Symptoms That Need Prompt Attention

Patients and caregivers should contact the healthcare team right away if symptoms such as headache, confusion, dizziness, vision changes, nausea, difficulty walking, weakness, seizures, or sudden neurologic changes occur. These symptoms do not always mean ARIA is present, but they deserve prompt medical evaluation.

Leqembi and APOE ε4 Testing

Before starting Leqembi, testing for APOE ε4 status is recommended to help estimate ARIA risk. People who have two copies of the APOE ε4 gene variant have a higher risk of ARIA, including symptomatic and serious ARIA, compared with noncarriers or people with one copy.

This genetic testing can raise emotional and family questions, so it should come with a careful conversation. The result may affect how a patient and family weigh the benefits and risks of treatment, but not having the test does not automatically mean a person cannot receive Leqembi. It does mean the team has less information about that person’s risk category.

What If a Dose Is Missed?

Missed IV Infusion

If a Leqembi IV infusion is missed, the next dose should be administered as soon as possible. The clinic will help reschedule and adjust the calendar. Patients should not try to “make up” the dose on their own or change the schedule without medical guidance.

Missed Leqembi IQLIK Dose

If a scheduled weekly Leqembi IQLIK maintenance dose is missed, it may be administered as soon as possible up to 6 days after the missed dose. The next dose is then given on the regularly scheduled day, and the original schedule is resumed.

If more time has passed or there is any confusion, call the prescribing team. With Leqembi, guessing is not a strategy. It is more like trying to assemble furniture without instructions, except the furniture is your treatment plan.

Common Side Effects Related to Leqembi Dosing

Side effects can vary by person and by route of administration. With IV Leqembi, common adverse reactions include infusion-related reactions, headache, and ARIA findings on MRI. Infusion reactions may happen during the infusion or after it is completed.

With Leqembi IQLIK, injection-related reactions may occur. Local reactions can include redness, swelling, warmth, pain, itching, bruising, rash, or firmness at the injection site. Systemic reactions, such as headache, fever, or fatigue, may also occur but have been reported less often.

Any serious allergic reaction, such as swelling of the face or throat, difficulty breathing, severe rash, or symptoms of anaphylaxis, requires emergency medical care.

Who Should Be Extra Careful With Leqembi?

Leqembi may not be appropriate for everyone. Extra caution is especially important for people with MRI findings suggesting a higher bleeding risk, people with a history of certain brain bleeding events, and people who need anticoagulant therapy or thrombolytic medications.

Because ARIA symptoms can resemble stroke symptoms, emergency teams should know if a patient is taking Leqembi. This matters because treatments used for stroke, such as thrombolytic therapy, may require special caution in someone receiving an anti-amyloid monoclonal antibody.

Practical Questions to Ask Before Starting Leqembi

Patients and caregivers may want to bring a written list of questions to the neurology appointment. Good questions include:

• Am I in the stage of Alzheimer’s disease where Leqembi may be appropriate?
• How will amyloid beta pathology be confirmed?
• What MRI schedule will I need?
• Should I have APOE ε4 genetic testing?
• How long will each infusion visit take from arrival to departure?
• What symptoms should trigger an urgent call?
• After 18 months, would IV or subcutaneous maintenance dosing make more sense for me?
• How will treatment costs, insurance coverage, transportation, and caregiver time be handled?

Leqembi Dosage and Real-Life Treatment Planning

The Leqembi dosage schedule is medically precise, but the lived experience is also logistical. A twice-monthly infusion schedule can affect transportation, work calendars, caregiver availability, clinic access, and fatigue. For many families, the question is not only “What is the dose?” but also “Can we realistically keep this schedule going?”

That is why maintenance options matter. After 18 months, some patients may prefer less frequent IV visits, while others may prefer weekly subcutaneous injections if they are eligible and properly trained. The best choice depends on medical risk, comfort with injections, caregiver support, local clinic access, and the treating specialist’s judgment.

Experience Section: What Leqembi Dosage Can Feel Like for Patients and Caregivers

For many families, starting Leqembi is less like beginning a simple prescription and more like joining a carefully managed treatment program. The first experience is often the evaluation phase. A patient may already have memory concerns, but Leqembi requires more than a quick conversation about forgetfulness. The care team may review cognitive testing, medical history, brain imaging, amyloid testing, medication lists, and whether the person can safely undergo repeated MRIs. This can feel slow, especially when families are eager to “do something,” but the screening process is there for safety.

The first infusion visit can also feel emotionally loaded. Some patients feel hopeful; others feel nervous; many feel both before they even sit in the chair. The infusion itself is not usually dramatic. A nurse places the IV, the medication runs over about an hour, and the team monitors for reactions. The room may look more like a quiet clinic than a high-tech movie scene. There may be warm blankets, blood pressure checks, and the gentle background soundtrack of medical machines doing their best impression of a refrigerator.

Caregivers often become the unofficial project managers of Leqembi treatment. They track appointments, watch for symptoms, arrange transportation, remember MRI dates, and help communicate changes to the healthcare team. A caregiver may notice that the biggest challenge is not the infusion itself but the rhythm: every two weeks means the calendar fills up quickly. Miss one appointment because of weather, illness, or transportation trouble, and the care team has to help get the schedule back on track.

The MRI monitoring period can be another emotional checkpoint. Even when a patient feels fine, the scan may detect changes that require pausing treatment or watching more closely. That uncertainty can be stressful. Families should know that pausing treatment does not mean anyone failed. It means the monitoring system did what it was designed to do: identify a possible safety issue before charging ahead blindly.

After 18 months, the conversation often shifts. Families may ask whether continuing every-two-week IV infusions still makes sense, whether monthly IV maintenance would reduce the burden, or whether weekly Leqembi IQLIK injections at home could be practical. Some people like the reassurance of clinic-based infusions. Others may welcome fewer trips. Still others may decide that home injection sounds convenient until they realize someone has to be trained, organized, and comfortable pressing the autoinjector against the skin every week.

The most helpful mindset is realistic hope. Leqembi is not a memory reset button. It is a treatment with potential benefits, serious risks, and a demanding schedule. Families who do best are often the ones who ask practical questions early, keep a shared calendar, report symptoms quickly, and treat the care team as partners rather than distant gatekeepers. Leqembi dosage is measured in milligrams, but the treatment experience is measured in planning, patience, and steady communication.

Conclusion

Leqembi dosage begins with 10 mg/kg by IV infusion once every 2 weeks, given over approximately one hour. After about 18 months, patients may continue the same schedule or transition to maintenance therapy, such as 10 mg/kg IV once every 4 weeks or Leqembi IQLIK 360 mg once weekly as a subcutaneous injection, depending on eligibility and clinical judgment.

The key takeaway is simple: Leqembi is not a casual medication. It requires amyloid confirmation, MRI monitoring, risk discussion, weight-based dosing, and a dependable care plan. For the right patient, under the right supervision, it may be an important part of early Alzheimer’s disease treatment. But the dose, schedule, and route should always be decided by a qualified healthcare professional.

Note: This article is for educational purposes only and should not replace professional medical advice. Patients should follow the dosing instructions provided by their prescribing clinician and official medication guide.